The team will develop a new medical tool to facilitate the removal of blood clots in blood vessels after a stroke in a safer and more effective manner.

Her nomination means that she will represent UPF in the national competition held annually.

Areas of interest include the development of new drugs, medical devices and digital health solutions, as well as new therapies and diagnostic technologies.

The HUVH Biobank has been recognized for its sustainability and efficiency in laboratory cold storage.

The Lancet Neurology publishes the new criteria, the result of a global expert consensus led by Dr Xavier Montalban.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

First awarded in 2015 and renewed in 2021, this 2025 renewal reaffirms VHIR’s commitment to fostering a transparent, ethical, inclusive, and high-quality research environment.

The annual event offered a space for dialogue between the scientific community and society on how to address the future of ageing through research and innovation.

The event, organized jointly by Vall d’Hebron and the Mayo Clinic, offered specialized talks reviewing the latest developments and challenges in the field of nephrology.

Genetic susceptibility to developing ADHD shows the strongest association with mental health problems during childhood and adolescence, compared to genetic risk for other psychiatric conditions.

Critical thinking enables these professionals to analyse each clinical situation more reflectively and rigorously in order to improve patient care.

 FIT is an initiative aimed at funding projects developed at VHIR with high impact and market transfer potential.

A retrospective study has been carried out with data from 11,000 patients to train artificial intelligence algorithms and adapt the Nora mobile application to different patient profiles.

Transaction expands Formation Bio's immunology pipeline with Phase 1 ready drug candidate.

15 researchers from the Rheumatology, Systemic Diseases and the Physiology and Pathophysiology of the Digestive Tract groups gave around 25 presentations.

Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss.

The study, involving a thousand participants from different regions of Spain, shows that diet influences the diversity and composition of the microbiota and, therefore, health.

The project, in which Vall d’Hebron participates, studied the Bimervax® vaccine in immunocompromised individuals and paediatric patients.

The treatment, licensed to Klotho Neurosciences, is based on a technology developed at the Universitat Autònoma de Barcelona (UAB) with the participation of VHIR.

El informe incluye los datos y los resultados científicos e institucionales más destacados del centro durante el año.

The aim of the initiative is to improve the management of innovation projects and their reach to patients and promote innovative and entrepreneurial culture.

ISMED-CLIM is a European project coordinated by the University of Cyprus and has 27 partners from 11 countries, including the Parc Sanitari Pere Virgili and the Vall d'Hebron Research Institute, which lead the regional working group.

The distinction from the Catalan Transplant Society will allow her to become a member of the Royal Academy of Medicine of Catalonia.

PAIR is an intergenerational initiative with people affected by Parkinson's disease and adolescents.